8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Apr 7, 2026·SEC
Material company update
Mar 26, 2026·SEC
Inhibikase Therapeutics, Inc.(IKT)Earnings, Financials & Key Ratios
IKT•NASDAQ
Price updated Jun 11, 2026
AboutInhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.Show more
- Revenue$0
- EBITDA-$52M-81.8%
- Net Income-$48M-75.4%
- EPS (Diluted)-0.49+57.8%
- ROE-36.05%+30.7%
- ROIC-108.03%-3.1%
IKT Key Insights
Inhibikase Therapeutics, Inc. (IKT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.9x book value
✗Weaknesses
- ✗Profits declining 76.1% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 41.7% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when IKT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IKT Price & Volume
Inhibikase Therapeutics, Inc. (IKT) stock price & volume — 10-year historical chart
Loading chart...
IKT Growth Metrics
Inhibikase Therapeutics, Inc. (IKT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-39.43%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM66.87%
Return on Capital
10 Years-72.55%
5 Years-67.77%
3 Years-72.39%
Last Year-38.82%
IKT Recent Earnings
Inhibikase Therapeutics, Inc. (IKT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)
Q2 2026Latest
May 12, 2026EPS
$0.10
Est $0.10
+0.0%
Revenue
—
Q2 2026
Mar 26, 2026EPS
$0.09
Est $0.12
+25.0%
Revenue
—
Q4 2025
Nov 14, 2025EPS
$0.13
Est $0.13
+0.0%
Revenue
—
Q3 2025
Aug 14, 2025EPS
$0.11
Est $0.09
-22.2%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.10vs $0.10+0.0% | — |
| Q2 2026 | Mar 26, 2026 | $0.09vs $0.12+25.0% | — |
| Q4 2025 | Nov 14, 2025 | $0.13vs $0.13+0.0% | — |
| Q3 2025 | Aug 14, 2025 | $0.11vs $0.09-22.2% | — |
Based on last 12 quarters of dataView full earnings history →
IKT Peer Comparison
Inhibikase Therapeutics, Inc. (IKT) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PRTA | 432.44M | 8.26 | -1.82 | -92.84% | -260.92% | -49.88% | 0.05 | |
 ACAD | 3.66B | 21.39 | 9.34 | 11.87% | 34.3% | 35.65% | 0.04 | |
 SAVA | 63.77M | 1.32 | -2.54 | -95.77% | ||||
 NRXP | 67.76M | 3.92 | -2.93 | -10.7% | ||||
 INVA | 1.66B | 22.44 | 6.80 | 18.52% | 118.91% | 47.59% | 0.23 | |
 AVXL | 231.68M | 2.50 | -4.63 | -38.76% | ||||
 ACIU | 230.01M | 2.26 | -2.58 | -86.92% | -19.69% | -101.6% | 0.10 | |
 ATHA | 17.12M | 4.34 | -0.17 | -381.01% | 0.03 |
Compare IKT vs Peers
Inhibikase Therapeutics, Inc. (IKT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IKT Income Statement
Inhibikase Therapeutics, Inc. (IKT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 2.06M | 4.04M | 1.12M | 698.47K | 3.1M | 123.44K | 260.5K | 0 | 0 | 0 |
Revenue Growth % | 113.04% | 96.07% | -72.22% | -37.79% | 343.92% | -96.02% | 111.03% | -100% | - | - |
Cost of Goods Sold | 1.76M | 3.65M | 2.55M | 893.8K | 11.36M | 6.72K | 13.62M | 26.27K | 0 | 0 |
COGS % of Revenue | 85.19% | 90.25% | 227.36% | 127.97% | 366.35% | 5.45% | 5227.77% | - | - | - |
Gross Profit | 305.25K▲ 0% | 393.85K▲ 29.0% | -1.43M▼ 463.1% | -195.33K▲ 86.3% | -8.26M▼ 4127.9% | 116.72K▲ 101.4% | -13.36M▼ 11544.6% | -26.27K▲ 99.8% | 0▲ 100.0% | 0▲ 0% |
Gross Margin % | 14.81% | 9.75% | -127.36% | -27.97% | -266.35% | 94.55% | -5127.77% | - | - | - |
Gross Profit Growth % | 152.27% | 29.03% | -463.08% | 86.34% | -4127.89% | 101.41% | -11544.65% | 99.8% | 100% | - |
Operating Expenses | 2.47M | 2.12M | 4.27M | 2.62M | 6.51M | 18.25M | 6.73M | 28.56M | 51.97M | 55.59M |
OpEx % of Revenue | 119.66% | 52.52% | 380.16% | 375.56% | 209.88% | 14780.72% | 2584.24% | - | - | - |
Selling, General & Admin | 710.38K | 2.52M | 0 | 0 | 0 | 6.21M | 6.73M | 11.38M | 23.56M | 25.68M |
SG&A % of Revenue | 34.47% | 62.26% | - | - | - | 5031.06% | 2584.24% | - | - | - |
Research & Development | 1.76M | 3.65M | 2.55M | 893.8K | 11.36M | 12.03M | 13.62M | 17.21M | 29.79M | 30.12M |
R&D % of Revenue | 85.19% | 90.25% | 227.36% | 127.97% | 366.35% | 9749.66% | 5227.77% | - | - | - |
Other Operating Expenses | 0 | 0 | 1.72M | 1.73M | -4.85M | 0 | -13.62M | -26.27K | -1.37M | -209.08K |
Operating Income | -405.13K▲ 0% | -2.12M▼ 423.8% | -5.7M▼ 168.5% | -2.82M▲ 50.5% | -14.77M▼ 423.9% | -18.13M▼ 22.8% | -20.09M▼ 10.8% | -28.59M▼ 42.3% | -51.97M▼ 81.8% | -55.59M▲ 0% |
Operating Margin % | -19.66% | -52.52% | -507.52% | -403.52% | -476.23% | -14686.17% | -7712.01% | - | - | - |
Operating Income Growth % | 33.94% | -423.81% | -168.51% | 50.54% | -423.9% | -22.77% | -10.82% | -42.31% | -81.8% | - |
EBITDA | 0 | 0 | 0 | 0 | 0 | -18.12M | -19.91M | -28.56M | -51.91M | -54.9M |
EBITDA Margin % | - | - | - | - | - | -14680.72% | -7643.91% | - | - | - |
EBITDA Growth % | - | - | - | - | - | - | -9.88% | -43.44% | -81.75% | -43.08% |
D&A (Non-Cash Add-back) | 405.13K | 2.12M | 5.7M | 2.82M | 14.77M | 6.72K | 177.4K | 26.27K | 60.5K | 47.84K |
EBIT | -405.13K | -2.12M | -5.7M | -2.82M | -14.77M | -18.05M | -20.09M | -27.52M | -53.35M | -55.8M |
Net Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 1.06M | 1.07M | 3.72M | 4.26M |
Interest Income | 30.95K | 0 | 24.84K | 29.4K | 19.92K | 74.45K | 1.06M | 1.07M | 3.72M | 4.26M |
Interest Expense | 0 | 30.33K | 24.84K | 29.4K | 19.92K | 74.45K | 0 | 0 | 0 | 0 |
Other Income/Expense | -30.95K | -30.33K | -24.84K | -29.4K | -19.92K | 74.45K | 1.06M | 1.07M | 3.72M | 4.63M |
Pretax Income | -436.07K▲ 0% | -2.15M▼ 393.6% | -5.72M▼ 165.9% | -2.85M▲ 50.2% | -14.79M▼ 419.2% | -18.05M▼ 22.1% | -19.03M▼ 5.4% | -27.52M▼ 44.6% | -48.26M▼ 75.4% | -50.96M▲ 0% |
Pretax Margin % | -21.16% | -53.27% | -509.73% | -407.73% | -476.88% | -14625.85% | -7304.75% | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -436.07K▲ 0% | -2.15M▼ 393.6% | -5.72M▼ 165.9% | -2.85M▲ 50.2% | -14.79M▼ 419.2% | -18.05M▼ 22.1% | -19.03M▼ 5.4% | -27.52M▼ 44.6% | -48.26M▼ 75.4% | -50.96M▲ 0% |
Net Margin % | -21.16% | -53.27% | -509.73% | -407.73% | -476.88% | -14625.85% | -7304.75% | - | - | - |
Net Income Growth % | 30.64% | -393.6% | -165.88% | 50.24% | -419.19% | -22.1% | -5.4% | -44.62% | -75.36% | -39.43% |
Net Income (Continuing) | -436.07K | -2.15M | -5.72M | -2.85M | -14.79M | -18.05M | -19.03M | -27.52M | -48.26M | -50.96M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.25▲ 0% | -1.61▼ 544.0% | -3.34▼ 107.5% | -1.72▲ 48.5% | -4.88▼ 183.7% | -4.26▲ 12.7% | -3.57▲ 16.2% | -1.16▲ 67.5% | -0.49▲ 57.8% | -0.52▲ 0% |
EPS Growth % | 47.92% | -544% | -107.45% | 48.5% | -183.72% | 12.7% | 16.2% | 67.51% | 57.76% | 66.87% |
EPS (Basic) | -0.25 | -1.61 | -3.34 | -1.72 | -4.88 | -4.26 | -3.57 | -1.16 | -0.49 | - |
Diluted Shares Outstanding | 1.72M | 1.34M | 1.72M | 1.68M | 3.03M | 4.2M | 5.33M | 69.36M | 98.31M | 98.31M |
Basic Shares Outstanding | 1.72M | 1.34M | 1.72M | 1.68M | 3.03M | 4.2M | 5.33M | 69.36M | 98.31M | 98.31M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
IKT Balance Sheet
Inhibikase Therapeutics, Inc. (IKT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 198.07K | 1.25M | 35.38K | 14.78M | 42.47M | 24.37M | 14.21M | 98.45M | 180.11M | 172.18M |
Cash & Short-Term Investments | 16.66K | 379.56K | 18.46K | 13.95M | 40.75M | 23.05M | 13.25M | 97.54M | 178.76M | 170.37M |
Cash Only | 16.66K | 379.56K | 18.46K | 13.95M | 40.75M | 7.19M | 9.17M | 56.49M | 139.22M | 49.57M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 15.86M | 4.09M | 41.05M | 39.54M | 120.8M |
Accounts Receivable | 180.78K | 472.94K | 0 | 0 | 110.14K | 39.88K | 0 | 0 | 0 | 0 |
Days Sales Outstanding | 32.02 | 42.72 | - | - | 12.97 | 117.92 | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 625 | 0 | 16.92K | 54.84K | 107K | 1.12M | 739.18K | 106.31K | 1.35M | 1.81M |
Total Non-Current Assets | 87.1K | 1.59M | 2.87K | 0 | 0 | 565.17K | 295.6K | 148.54K | 1.1M | 1.16M |
Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 565.17K | 295.6K | 148.54K | 0 | 0 |
Fixed Asset Turnover | - | - | - | - | - | 0.22x | 0.88x | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 87.1K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 1.59M | 2.87K | 0 | 0 | 0 | 0 | 0 | 1.1M | 1.16M |
Total Assets | 285.17K▲ 0% | 2.85M▲ 898.2% | 38.25K▼ 98.7% | 14.78M▲ 38543.6% | 42.47M▲ 187.3% | 24.94M▼ 41.3% | 14.51M▼ 41.8% | 98.6M▲ 579.7% | 181.2M▲ 83.8% | 173.33M▲ 0% |
Asset Turnover | 7.23x | 1.42x | 29.35x | 0.05x | 0.07x | 0.00x | 0.02x | - | - | 0.00x |
Asset Growth % | 75.03% | 898.17% | -98.66% | 38543.56% | 187.3% | -41.28% | -41.83% | 579.69% | 83.78% | 2792.78% |
Total Current Liabilities | 1.73M | 3.62M | 4.25M | 4.72M | 4.05M | 3.7M | 3.44M | 3.73M | 8.3M | 5.71M |
Accounts Payable | 353.52K | 954.24K | 1M | 1.72M | 1.09M | 1.15M | 646.77K | 943.02K | 1.16M | 1.59M |
Days Payables Outstanding | 73.5 | 95.5 | 143.23 | 702.67 | 35.02 | 62.5K | 17.33 | 13.1K | - | - |
Short-Term Debt | 459.96K | 233.73K | 98.42K | 42.53K | 248.91K | 0 | 381.78K | 0 | 0 | 0 |
Deferred Revenue (Current) | 5.64K | 262.37K | 1.43M | 2.33M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 907.05K | 0 | 0 | 0 | 0 | 0 | 635.45K | 0 | 7.14M | 4.12M |
Current Ratio | 0.11x | 0.35x | 0.01x | 3.13x | 10.47x | 6.59x | 4.13x | 26.37x | 21.70x | 30.14x |
Quick Ratio | 0.11x | 0.35x | 0.01x | 3.13x | 10.47x | 6.59x | 4.13x | 26.37x | 21.70x | 30.14x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 1.45M | 275.38K | 276.46K | 0 | 205.45K | 90.12K | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 275.38K | 276.46K | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 205.45K | 90.12K | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1.73M | 3.62M | 4.53M | 5M | 4.05M | 3.9M | 3.53M | 3.73M | 8.3M | 5.71M |
Total Debt | 459.96K | 233.73K | 373.79K | 319K | 248.91K | 351.29K | 622K | 110.52K | 0 | 0 |
Net Debt | 443.3K | -145.83K | 355.34K | -13.63M | -40.5M | -6.84M | -8.54M | -56.38M | -139.22M | -49.57M |
Debt / Equity | - | - | - | 0.03x | 0.01x | 0.02x | 0.06x | 0.00x | - | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.90x |
Interest Coverage | - | -69.96x | -229.44x | -95.86x | -741.16x | -242.49x | - | - | - | - |
Total Equity | -1.44M▲ 0% | -777.97K▲ 46.0% | -4.49M▼ 477.1% | 9.78M▲ 317.9% | 38.42M▲ 292.6% | 21.04M▼ 45.2% | 10.98M▼ 47.8% | 94.87M▲ 764.2% | 172.9M▲ 82.3% | 167.62M▲ 0% |
Equity Growth % | -6.61% | 46.01% | -477.15% | 317.91% | 292.62% | -45.24% | -47.81% | 764.16% | 82.26% | 15487.57% |
Book Value per Share | -0.84 | -0.58 | -2.61 | 5.84 | 12.66 | 5.01 | 2.06 | 1.37 | 1.76 | 1.71 |
Total Shareholders' Equity | -1.44M | -777.97K | -4.49M | 9.78M | 38.42M | 21.04M | 10.98M | 94.87M | 172.9M | 167.62M |
Common Stock | 8.92K | 8.18K | 8.18K | 10.05K | 25.16K | 4.22K | 6.19K | 69.36K | 131.69K | 132.03K |
Retained Earnings | -4.31M | -6.46M | -12.18M | -15.03M | -29.82M | -47.87M | -66.9M | -94.42M | -142.68M | -159.06M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 104.72K | 877 | -37.25K | 21.8K | -26.29K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IKT Cash Flow Statement
Inhibikase Therapeutics, Inc. (IKT) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -126.39K | 714.99K | -338.29K | -1.13M | -14.3M | -17.35M | -18.09M | -19.15M | -27.79M | -35.74M |
Operating CF Margin % | -6.13% | 17.69% | -30.13% | -161.69% | -461.11% | -14056.31% | -6942.43% | - | - | - |
Operating CF Growth % | -327.39% | 665.69% | -147.31% | -233.84% | -1165.95% | -21.36% | -4.23% | -5.88% | -45.11% | -361.79% |
Net Income | -436.07K | -2.15M | -5.72M | -2.85M | -14.79M | -18.05M | -19.03M | -27.52M | -48.26M | -50.96M |
Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 6.72K | 177.4K | 26.27K | 60.5K | 47.85K |
Stock-Based Compensation | 300.66K | 642.23K | 1.44M | 573.7K | 1.53M | 458.15K | 500.15K | 8.14M | 15.31M | 8.74M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 534.62K | 709.27K | 2.32M | 1.61M | 721.63K | 67K | 31.54K | 0 | 5.05M | 7.75M |
Working Capital Changes | -32.76K | 1.52M | 1.63M | -464.64K | -1.76M | 171.18K | 234.76K | 204.93K | 55.92K | -1.32M |
Change in Receivables | -113.9K | -292.16K | 472.94K | 0 | -110.14K | 70.26K | 39.88K | 0 | 0 | 0 |
Change in Inventory | 0 | 950.65K | -54.9K | 0 | 1.3M | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -78.27K | 600.72K | 47.46K | -247.07K | -630.9K | 61.4K | -504.41K | 271.78K | 146.83K | -104.75K |
Cash from Investing | 0 | 87.1K | 0 | 0 | 0 | -16.01M | 11.66M | -37M | 2.05M | -99.49M |
Capital Expenditures | 0 | 0 | 0 | 0 | 0 | -243.25K | -14.24K | 0 | -452.02K | -452.02K |
CapEx % of Revenue | - | - | - | - | - | 197.06% | 5.47% | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 243.25K | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 87.1K | 0 | 0 | 0 | -243.25K | 0 | 0 | 0 | 452.02K |
Cash from Financing | 131.02K | -439.19K | -22.81K | 15.06M | 41.09M | -204.77K | 8.41M | 103.48M | 108.46M | 111.36M |
Debt Issued (Net) | 0 | -26.31K | -22.81K | 272.8K | -42.53K | -248.91K | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 1.18M | 0 | 14.79M | 41.14M | 44.14K | 8.41M | 103.48M | 108.46M | 111.33M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 131.02K | -1.59M | 0 | 0 | 848 | 0 | 0 | 0 | 0 | 31.62K |
Net Change in Cash | 4.63K▲ 0% | 362.89K▲ 7739.5% | -361.1K▼ 199.5% | 13.94M▲ 3959.1% | 26.8M▲ 92.3% | -33.56M▼ 225.2% | 1.98M▲ 105.9% | 47.33M▲ 2294.3% | 82.73M▲ 74.8% | -23.87M▲ 0% |
Free Cash Flow | -126.39K▲ 0% | 714.99K▲ 665.7% | -338.29K▼ 147.3% | -1.13M▼ 233.8% | -14.3M▼ 1165.9% | -17.59M▼ 23.1% | -18.1M▼ 2.9% | -19.15M▼ 5.8% | -27.79M▼ 45.1% | -36.19M▲ 0% |
FCF Margin % | -6.13% | 17.69% | -30.13% | -161.69% | -461.11% | -14253.37% | -6947.9% | - | - | - |
FCF Growth % | -327.39% | 665.69% | -147.31% | -233.84% | -1165.95% | -23.06% | -2.87% | -5.79% | -45.11% | -86.72% |
FCF per Share | -0.07 | 0.54 | -0.20 | -0.67 | -4.71 | -4.19 | -3.39 | -0.28 | -0.28 | -0.37 |
FCF Conversion (FCF/Net Income) | 0.29x | -0.33x | 0.06x | 0.40x | 0.97x | 0.96x | 0.95x | 0.70x | 0.58x | 0.71x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IKT Key Ratios
Inhibikase Therapeutics, Inc. (IKT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | -107.58% | -61.35% | -60.74% | -118.88% | -52% | -36.05% | -41.31% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | -224.5% | -181.18% | -104.8% | -108.03% | -88.38% |
| Gross Margin | 14.81% | 9.75% | -127.36% | -27.97% | -266.35% | 94.55% | -5127.77% | - | - | - |
| Net Margin | -21.16% | -53.27% | -509.73% | -407.73% | -476.88% | -14625.85% | -7304.75% | - | - | - |
| Debt / Equity | - | - | - | 0.03x | 0.01x | 0.02x | 0.06x | 0.00x | - | 0.00x |
| Interest Coverage | - | -69.96x | -229.44x | -95.86x | -741.16x | -242.49x | - | - | - | - |
| FCF Conversion | 0.29x | -0.33x | 0.06x | 0.40x | 0.97x | 0.96x | 0.95x | 0.70x | 0.58x | 0.71x |
| Revenue Growth | 113.04% | 96.07% | -72.22% | -37.79% | 343.92% | -96.02% | 111.03% | -100% | - | - |
Related:IKT Dividend History·IKT Revenue History·IKT Price History·IKT P/E History·IKT Financial Ratios·IKT Institutional Holders
IKT SEC Filings & Documents
Inhibikase Therapeutics, Inc. (IKT) SEC filings — annual & quarterly reports (10-K, 10-Q)
IKT Frequently Asked Questions
Inhibikase Therapeutics, Inc. (IKT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Inhibikase Therapeutics, Inc. (IKT) grew revenue by 0.0% over the past year. Growth has been modest.
Inhibikase Therapeutics, Inc. (IKT) reported a net loss of $51.0M for fiscal year 2025.
Dividend & Returns
Inhibikase Therapeutics, Inc. (IKT) has a return on equity (ROE) of -36.0%. Negative ROE indicates the company is unprofitable.
Inhibikase Therapeutics, Inc. (IKT) had negative free cash flow of $36.2M in fiscal year 2025, likely due to heavy capital investments.